ONC IN-CYT
OraLiva's ONC IN-CYT platform is a pipeline of oncology diagnostics leveraging cross indication biomarker cyto-signatures
OraLiva is launching its platform with a focus on oral cancer, leveraging its proprietary technology, diagnostic models, and cross-indication biomarkers to build a robust pipeline of oncology tests. Market penetration in oral cancer will serve as both clinical validation and a commercial beachhead, demonstrating the power of OraLiva’s multi-phased business model while establishing brand recognition among key provider and patient populations.
Transformative medical microdevice platform yields clinically actionable data anywhere
AI empowered & data-driven fingerprints for early disease detection
Powerful diagnostic ecosystem with potential to change standard of care
Elements of a Smart Diagnostics Platform
+ Integrated point-of-care sensor suite
+ Multiple data streams
+ Illness and wellness disease fingerprints
+ Intuitive reporting for both expert and nonexperts
How It Works
Save $100k In Treatment Costs
About 10% of the US population suffer from complications of oral lesions. Today doctors and dentists lack trusted tools to evaluate these oral lesions. In far too many cases these lesions become malignant.
​
Late detection of different types of solid tumor cancers remains an issue resulting in higher costs for treatment, hospital stays, in addition to often disastrous patient outcomes. OraLiva Inc. has developed a novel cytology platform to detect the presence of oral, lung, esophageal and colorectal cancer using common biomarker signatures.
Powerful AI Methods Linked to the Largest Oral Lesion Cytology Databases
International NIH study of 999 patients
OraLiva Inc. sees cancer better than anyone else
This cytology platform has revealed 128 new variables for better discrimination